(Q36745702)

16 August 2017

1 reference

title

Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure (English)

1 reference

16 August 2017

0 references

Garry L Jennings

2

0 references

author name string

Julie R McMullen

series ordinal

1

1 reference

16 August 2017

publication date

1 April 2007

1 reference

Clinical and Experimental Pharmacology and Physiology

16 August 2017

published in

1 reference

16 August 2017

volume

34

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

255-262

1 reference

Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04585.X

Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04585.X

The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04585.X

The effects of changes in physical activity on major cardiovascular risk factors, hemodynamics, sympathetic function, and glucose utilization in man: a controlled study of four levels of activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04585.X

10.1111/J.1440-1681.2007.04585.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference